Abstract
Goals
The aim of our study was to evaluate the incidence of venous toxicity induced by vinorelbine administration in patients who received a preventive therapy with defibrotide.
Patients and methods
From July 1996 to July 2002 we treated 203 patients with vinorelbine, 51 with vinorelbine alone and 152 with vinorelbine in combination with other drugs via peripheral vein infusion. Of the 203 patients, 123 were male and 80 female with a median age of 67 years (range 18 to 82 years), and 118 were chemotherapy-naive. Defibrotide was delivered i.v. at a dose of 400 mg in 250 ml normal saline. After infusion of 125 ml over about 15 min, vinorelbine mixed with 10 ml normal saline was delivered as quick brief repeated pulses over 5 min through the plastic tube, followed by infusion of the remaining defibrotide. The specific Rittenberg scale was used to assess venous irritation episodes.
Results
Among a total of 1336 vinorelbine infusions, with a median of five infusions per patient, the incidence of venous irritation episodes graded according to Rittenberg scale was 1.1% (15), of which 0.6% (8) were grade 2 and 0.5% (7) grade 1. Globally, 15 patients (7.3%) developed venous toxicity after a median of 3 infusions (range 1–14), but no patient had more than one event.
Conclusion
Our findings support the use of defibrotide as an effective, safe and low-cost means for preventing vinorelbine-related venous damage.
Similar content being viewed by others
References
Blajman C, Balbiani L, Block J, et al (1999) A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer 85:1091–1097
Bonneterre J, Chevalier B, Focan C, et al (2001) Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). Ann Oncol 12:1683–1691
Coccaro M, Bochicchio AM, Capobianco AML, et al (2001) Long-term infusional system: complications in cancer patients. Tumori 87:308–311
Conroy T, Etienne PL, Adenis A, et al (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 14:164–170
Degardin M, Oliveira J, Geoffrois L, et al (1998) An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 9:1103–1107
Depierre A, Freyer G, Jassem J, et al (2001) Oral vinorelbine: feasibility and safety profile. Ann Oncol 12:1677–1681
Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66–72
Fumoleau P, Delgado FM, Delozier T, et al (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245–1252
Jassem J, Ramlau R, Karnicka-Mlodkowska H, et al (2001) A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 12:1375–1381
Le Chevalier T, Brisgand D, Douillard JY, et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367
Lozano M, Muro H, Triguboff E, et al (1995) A randomized trial for effective prevention of navelbine (NVB) related phlebitis (abstract 1766). Proc ASCO 14
Maisano R, Adamo V, Toscano G, et al (1997) Defibrotide in the prevention of venous irritation by vinorelbine administration. Anticancer Res 17:2775–2778
Pignata S, Silvestro G, Ferrari E, et al (1999) Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol 17:756–760
Rittenberg CN, Gralla RJ, Rehmeyer TA (1995) Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine). Oncol Nurs Forum 22:707–710
Thurlimann B, Bachmann I (1992) Effective prevention of chemotherapy-induced phlebitis by low-dose heparin: a prospective randomized trial. Ann Oncol 4:311–313
Vassilomanolakis M, Koumakis G, Barbounis V, et al (2001) Prevention of vinorelbine phlebitis with cimetidine. A two-step design study. Support Care Cancer 9:108–111
Vici P, Colucci G, Gebbia V, et al (2002) First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. J Clin Oncol 20:2689–2694
Wozniak AJ, Crowley JJ, Balcerzak SP, et al (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16:2459–2465
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mare, M., Maisano, R., Caristi, N. et al. Venous damage prevention by defibrotide in vinorelbine-treated patients. Support Care Cancer 11, 593–596 (2003). https://doi.org/10.1007/s00520-003-0479-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-003-0479-z